摘要
自从1944年发现链霉素以来,结核病的治疗与抗结核药物的研发密切相关。世界卫生组织(WHO)将抗结核药物分为5组,其中第三组的氟喹诺酮类及第二组注射类的抗结核药物是治疗耐药结核病的关键药物。近几年来,新型抗结核药物如贝达喹啉、德拉马尼(Delamanid)、PA-824相继问世,已知具有抗结核作用的抗菌药物如利奈唑胺、新一代氟喹诺酮类,原有药物新用途的开发如氯法齐明,环丝氨酸的应用等,这些药物在耐药结核病治疗上发挥了重要作用。随着抗结核新药物的研发,结核病的疫情会逐渐下降。
Since 1994 when streptomycin appeared, the treatment of tuberculosis （TB） has been closely associated with the research and development of anti-TB drugs. WHO has divided all the anti-TB drugs into five groups. ＂ihe second group, i.e., injectable anti- TB drugs, and the third group, i.e., fluoroquinolone, are the key drugs for TB treatment. In recent years, new anti-TB drugs such as bedaquiline, delamanid and PA-824 appeared. Some old antibiotics were found to have new activity against TB. And some old anti- TB drugs such as clofazimine and cycloserine, began to be researched for new use. All these drugs above played an important role for the treatment of resistant TB. With the development of new anti-TB drugs, the epidemic situation of TB will be improved in the future.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2015年第8期655-656,660,共3页
Chinese Journal of Practical Internal Medicine
关键词
管理指南
抗结核药物
manage guideline
anti-tuberculosis drugs
